Literature DB >> 11286939

Tumorigenesis in neurofibromatosis: new insights and potential therapies.

N Reed1, D H Gutmann.   

Abstract

The neurofibromatoses NF1 and NF2 are inherited cancer predisposition syndromes in which affected individuals are prone to development of mostly benign, but occasionally malignant, tumors. The NF1 and NF2 genes function as tumor suppressor genes (negative growth regulators), such that their loss of expression predisposes to tumor formation. Neurofibromin, the protein product of the NF1 gene, acts as a negative regulator of the ras proto-oncogene, to reduce cell growth. Merlin, the NF2 gene product, is involved in regulating cell proliferation and motility, and probably plays a role in integrating multiple cell-signaling pathways. By understanding the function of these tumor suppressors, we have a unique opportunity to develop targeted pharmacotherapeutic interventions for these disorders.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11286939     DOI: 10.1016/s1471-4914(01)01955-4

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  10 in total

1.  Inhibition of Cdc42-mediated activation of mixed lineage kinase 3 by the tumor suppressor protein merlin.

Authors:  Yu Zhan; Deborah N Chadee
Journal:  Small GTPases       Date:  2010-11

Review 2.  Neurocognitive dysfunction in children with neurofibromatosis type 1.

Authors:  Tena L Rosser; Roger J Packer
Journal:  Curr Neurol Neurosci Rep       Date:  2003-03       Impact factor: 5.081

Review 3.  Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival.

Authors:  Ivan Stamenkovic; Qin Yu
Journal:  Curr Protein Pept Sci       Date:  2010-09       Impact factor: 3.272

4.  Proposing the use of dental pulp stem cells as a suitable biological model of neurofibromatosis type 1.

Authors:  Paula Nascimento Almeida; Gustavo Torres Souza; Camila Maurmann de Souza; Rafaella Souza Salomão de Zanette; Claudinéia Pereira Maranduba; João Vitor Paes Rettore; Marcelo Oliveira de Santos; Antônio Márcio Resende do Carmo; Carlos Magno Costa da Maranduba; Fernando Sá de Silva
Journal:  Childs Nerv Syst       Date:  2014-12-06       Impact factor: 1.475

5.  p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.

Authors:  Hoi Yee Chow; Dina Stepanova; Jennifer Koch; Jonathan Chernoff
Journal:  PLoS One       Date:  2010-11-02       Impact factor: 3.240

6.  Genetic modeling of Ras-induced human rhabdomyosarcoma.

Authors:  Corinne M Linardic; Christopher M Counter
Journal:  Methods Enzymol       Date:  2008       Impact factor: 1.600

7.  Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity.

Authors:  Pierig Lepont; John T Stickney; Lauren A Foster; Jin-Jun Meng; Robert F Hennigan; Wallace Ip
Journal:  Mutat Res       Date:  2007-08-06       Impact factor: 2.433

8.  Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridisation.

Authors:  C Warren; L A James; R T Ramsden; A Wallace; M E Baser; J M Varley; D G Evans
Journal:  J Med Genet       Date:  2003-11       Impact factor: 6.318

9.  Succinate Dehydrogenase Subunit B (SDHB) Is Expressed in Neurofibromatosis 1-Associated Gastrointestinal Stromal Tumors (Gists): Implications for the SDHB Expression Based Classification of Gists.

Authors:  Jeanny H Wang; Jerzy Lasota; Markku Miettinen
Journal:  J Cancer       Date:  2011-02-16       Impact factor: 4.207

10.  Regulation of mixed lineage kinase 3 is required for Neurofibromatosis-2-mediated growth suppression in human cancer.

Authors:  Y Zhan; N Modi; A M Stewart; R I Hieronimus; J Liu; D H Gutmann; D N Chadee
Journal:  Oncogene       Date:  2010-10-04       Impact factor: 9.867

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.